nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—SLC6A4—epilepsy syndrome	0.294	0.587	CbGaD
Methylphenidate—CYP2D6—epilepsy syndrome	0.207	0.413	CbGaD
Methylphenidate—SLC6A2—locus ceruleus—epilepsy syndrome	0.00923	0.147	CbGeAlD
Methylphenidate—SLC6A3—telencephalic ventricle—epilepsy syndrome	0.00542	0.0866	CbGeAlD
Methylphenidate—SLC6A2—autonomic nervous system—epilepsy syndrome	0.0049	0.0783	CbGeAlD
Methylphenidate—SLC6A3—ganglion—epilepsy syndrome	0.00338	0.0539	CbGeAlD
Methylphenidate—SLC6A4—ganglion—epilepsy syndrome	0.00309	0.0494	CbGeAlD
Methylphenidate—SLC6A2—ganglion—epilepsy syndrome	0.00272	0.0435	CbGeAlD
Methylphenidate—SLC6A3—hindbrain—epilepsy syndrome	0.00256	0.0409	CbGeAlD
Methylphenidate—SLC6A4—hindbrain—epilepsy syndrome	0.00235	0.0375	CbGeAlD
Methylphenidate—SLC6A3—brainstem—epilepsy syndrome	0.00147	0.0234	CbGeAlD
Methylphenidate—SLC6A3—forebrain—epilepsy syndrome	0.00142	0.0226	CbGeAlD
Methylphenidate—SLC6A4—brainstem—epilepsy syndrome	0.00134	0.0215	CbGeAlD
Methylphenidate—SLC6A3—telencephalon—epilepsy syndrome	0.0013	0.0208	CbGeAlD
Methylphenidate—SLC6A4—forebrain—epilepsy syndrome	0.0013	0.0207	CbGeAlD
Methylphenidate—SLC6A4—telencephalon—epilepsy syndrome	0.00119	0.0191	CbGeAlD
Methylphenidate—SLC6A2—brainstem—epilepsy syndrome	0.00118	0.0189	CbGeAlD
Methylphenidate—SLC6A2—forebrain—epilepsy syndrome	0.00114	0.0182	CbGeAlD
Methylphenidate—CYP2D6—hindbrain—epilepsy syndrome	0.00113	0.0181	CbGeAlD
Methylphenidate—SLC6A2—telencephalon—epilepsy syndrome	0.00105	0.0168	CbGeAlD
Methylphenidate—SLC6A3—midbrain—epilepsy syndrome	0.000935	0.0149	CbGeAlD
Methylphenidate—Hexylcaine—SCN3A—epilepsy syndrome	0.000913	0.117	CrCbGaD
Methylphenidate—SLC6A3—spinal cord—epilepsy syndrome	0.000913	0.0146	CbGeAlD
Methylphenidate—SLC6A4—midbrain—epilepsy syndrome	0.000857	0.0137	CbGeAlD
Methylphenidate—SLC6A4—spinal cord—epilepsy syndrome	0.000836	0.0133	CbGeAlD
Methylphenidate—SLC6A2—medulla oblongata—epilepsy syndrome	0.000826	0.0132	CbGeAlD
Methylphenidate—SLC6A3—head—epilepsy syndrome	0.000811	0.0129	CbGeAlD
Methylphenidate—SLC6A3—nervous system—epilepsy syndrome	0.000769	0.0123	CbGeAlD
Methylphenidate—SLC6A4—head—epilepsy syndrome	0.000743	0.0119	CbGeAlD
Methylphenidate—SLC6A3—central nervous system—epilepsy syndrome	0.00074	0.0118	CbGeAlD
Methylphenidate—SLC6A3—cerebellum—epilepsy syndrome	0.000724	0.0115	CbGeAlD
Methylphenidate—SLC6A4—nervous system—epilepsy syndrome	0.000705	0.0112	CbGeAlD
Methylphenidate—SLC6A4—central nervous system—epilepsy syndrome	0.000678	0.0108	CbGeAlD
Methylphenidate—SLC6A2—head—epilepsy syndrome	0.000654	0.0104	CbGeAlD
Methylphenidate—CYP2D6—brainstem—epilepsy syndrome	0.000648	0.0103	CbGeAlD
Methylphenidate—Hexylcaine—SCN1A—epilepsy syndrome	0.000641	0.0824	CrCbGaD
Methylphenidate—CYP2D6—forebrain—epilepsy syndrome	0.000626	0.00999	CbGeAlD
Methylphenidate—SLC6A2—nervous system—epilepsy syndrome	0.00062	0.0099	CbGeAlD
Methylphenidate—SLC6A2—central nervous system—epilepsy syndrome	0.000597	0.00953	CbGeAlD
Methylphenidate—SLC6A3—brain—epilepsy syndrome	0.000588	0.00938	CbGeAlD
Methylphenidate—CYP2D6—telencephalon—epilepsy syndrome	0.000575	0.00918	CbGeAlD
Methylphenidate—Hexylcaine—SCN2A—epilepsy syndrome	0.000565	0.0727	CrCbGaD
Methylphenidate—SLC6A4—brain—epilepsy syndrome	0.000539	0.0086	CbGeAlD
Methylphenidate—SLC6A2—brain—epilepsy syndrome	0.000474	0.00757	CbGeAlD
Methylphenidate—Cyclopentolate—CHRM3—epilepsy syndrome	0.000454	0.0583	CrCbGaD
Methylphenidate—Cyclopentolate—CHRM1—epilepsy syndrome	0.000423	0.0544	CrCbGaD
Methylphenidate—Hyoscyamine—CHRM3—epilepsy syndrome	0.000404	0.052	CrCbGaD
Methylphenidate—Homatropine Methylbromide—CHRM3—epilepsy syndrome	0.000382	0.0491	CrCbGaD
Methylphenidate—Hyoscyamine—CHRM1—epilepsy syndrome	0.000377	0.0485	CrCbGaD
Methylphenidate—CYP2D6—head—epilepsy syndrome	0.000358	0.00572	CbGeAlD
Methylphenidate—Homatropine Methylbromide—CHRM1—epilepsy syndrome	0.000356	0.0458	CrCbGaD
Methylphenidate—Atropine—CHRM3—epilepsy syndrome	0.000344	0.0442	CrCbGaD
Methylphenidate—Ipratropium bromide—CHRM3—epilepsy syndrome	0.00034	0.0437	CrCbGaD
Methylphenidate—CYP2D6—nervous system—epilepsy syndrome	0.00034	0.00542	CbGeAlD
Methylphenidate—CYP2D6—central nervous system—epilepsy syndrome	0.000327	0.00522	CbGeAlD
Methylphenidate—Atropine—CHRM1—epilepsy syndrome	0.000321	0.0412	CrCbGaD
Methylphenidate—CYP2D6—cerebellum—epilepsy syndrome	0.00032	0.0051	CbGeAlD
Methylphenidate—Ipratropium bromide—CHRM1—epilepsy syndrome	0.000317	0.0408	CrCbGaD
Methylphenidate—Hyoscyamine—CHRM2—epilepsy syndrome	0.000308	0.0396	CrCbGaD
Methylphenidate—Homatropine Methylbromide—CHRM2—epilepsy syndrome	0.000291	0.0374	CrCbGaD
Methylphenidate—Cyclopentolate—BCHE—epilepsy syndrome	0.000288	0.037	CrCbGaD
Methylphenidate—Atropine—CHRM2—epilepsy syndrome	0.000262	0.0337	CrCbGaD
Methylphenidate—CYP2D6—brain—epilepsy syndrome	0.00026	0.00414	CbGeAlD
Methylphenidate—Ipratropium bromide—CHRM2—epilepsy syndrome	0.000259	0.0333	CrCbGaD
Methylphenidate—Dexmethylphenidate—SLC6A4—epilepsy syndrome	0.000243	0.0313	CrCbGaD
Methylphenidate—Dexmethylphenidate—CYP2D6—epilepsy syndrome	0.000171	0.022	CrCbGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC35A2—epilepsy syndrome	0.000158	0.0019	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC35A3—epilepsy syndrome	0.000158	0.0019	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC12A5—epilepsy syndrome	0.000158	0.0019	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SYN1—epilepsy syndrome	0.000158	0.00189	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—NSF—epilepsy syndrome	0.000158	0.00189	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CLCN6—epilepsy syndrome	0.000157	0.00188	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CLCN2—epilepsy syndrome	0.000157	0.00188	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—SST—epilepsy syndrome	0.000157	0.00188	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NTRK2—epilepsy syndrome	0.000157	0.00188	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GAD2—epilepsy syndrome	0.000156	0.00187	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL1RN—epilepsy syndrome	0.000156	0.00187	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CHRNB2—epilepsy syndrome	0.000156	0.00187	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SLC2A1—epilepsy syndrome	0.000154	0.00184	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—STXBP1—epilepsy syndrome	0.000154	0.00184	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—epilepsy syndrome	0.000152	0.00182	CbGpPWpGaD
Methylphenidate—SLC6A4—Monoamine Transport—TNF—epilepsy syndrome	0.000151	0.00181	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC1A1—epilepsy syndrome	0.00015	0.00179	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC6A4—epilepsy syndrome	0.000146	0.00175	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC17A7—epilepsy syndrome	0.000145	0.00174	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC4A10—epilepsy syndrome	0.000145	0.00173	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HBEGF—epilepsy syndrome	0.000145	0.00173	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TH—epilepsy syndrome	0.000144	0.00172	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIA4—epilepsy syndrome	0.000143	0.00171	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—ABAT—epilepsy syndrome	0.000143	0.00171	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CACNA1A—epilepsy syndrome	0.000143	0.00171	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—KCNJ10—epilepsy syndrome	0.000143	0.00171	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GABRA5—epilepsy syndrome	0.000143	0.00171	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CRH—epilepsy syndrome	0.000142	0.0017	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—SRC—epilepsy syndrome	0.000142	0.00169	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIK2—epilepsy syndrome	0.000141	0.00169	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC1A3—epilepsy syndrome	0.000141	0.00169	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC12A5—epilepsy syndrome	0.00014	0.00168	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC35A2—epilepsy syndrome	0.00014	0.00168	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC35A3—epilepsy syndrome	0.00014	0.00168	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CASP3—epilepsy syndrome	0.000138	0.00165	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C19—epilepsy syndrome	0.000138	0.00165	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—ARHGEF9—epilepsy syndrome	0.000137	0.00164	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC17A7—epilepsy syndrome	0.000137	0.00164	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GABRA1—epilepsy syndrome	0.000137	0.00164	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GABRB3—epilepsy syndrome	0.000137	0.00164	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP11A1—epilepsy syndrome	0.000137	0.00164	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2C19—epilepsy syndrome	0.000136	0.00163	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GAD1—epilepsy syndrome	0.000136	0.00162	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP11A1—epilepsy syndrome	0.000135	0.00162	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—epilepsy syndrome	0.000135	0.00161	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GLUL—epilepsy syndrome	0.000134	0.00161	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC8A1—epilepsy syndrome	0.000134	0.0016	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC2A1—epilepsy syndrome	0.000132	0.00158	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIA2—epilepsy syndrome	0.000132	0.00158	CbGpPWpGaD
Methylphenidate—SLC6A2—Monoamine Transport—TNF—epilepsy syndrome	0.00013	0.00156	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC6A4—epilepsy syndrome	0.00013	0.00155	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC1A3—epilepsy syndrome	0.000129	0.00155	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GABBR1—epilepsy syndrome	0.000129	0.00155	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC4A10—epilepsy syndrome	0.000128	0.00154	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC1A2—epilepsy syndrome	0.000127	0.00153	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIK1—epilepsy syndrome	0.000127	0.00153	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNA7—epilepsy syndrome	0.000127	0.00153	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—COX3—epilepsy syndrome	0.000127	0.00152	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—HMOX1—epilepsy syndrome	0.000127	0.00152	CbGpPWpGaD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—APOE—epilepsy syndrome	0.000126	0.00151	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIA1—epilepsy syndrome	0.000126	0.00151	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC6A1—epilepsy syndrome	0.000126	0.00151	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIN2A—epilepsy syndrome	0.000126	0.00151	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HBEGF—epilepsy syndrome	0.000124	0.00149	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GABRB2—epilepsy syndrome	0.000122	0.00146	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLCO1A2—epilepsy syndrome	0.00012	0.00144	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC8A2—epilepsy syndrome	0.00012	0.00144	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC9A6—epilepsy syndrome	0.00012	0.00144	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GAD2—epilepsy syndrome	0.00012	0.00143	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHRNB2—epilepsy syndrome	0.000119	0.00143	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—AVP—epilepsy syndrome	0.000119	0.00142	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC8A1—epilepsy syndrome	0.000119	0.00142	CbGpPWpGaD
Methylphenidate—Ipratropium bromide—CYP2D6—epilepsy syndrome	0.000119	0.0152	CrCbGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TH—epilepsy syndrome	0.000117	0.00141	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC2A1—epilepsy syndrome	0.000117	0.0014	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—BDNF—epilepsy syndrome	0.000117	0.0014	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—HTR7—epilepsy syndrome	0.000115	0.00138	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—epilepsy syndrome	0.000115	0.00138	CbGpPWpGaD
Methylphenidate—SLC6A3—Monoamine Transport—TNF—epilepsy syndrome	0.000115	0.00138	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC1A3—epilepsy syndrome	0.000115	0.00137	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GABRG2—epilepsy syndrome	0.000115	0.00137	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC8A3—epilepsy syndrome	0.000115	0.00137	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—KCNMA1—epilepsy syndrome	0.000114	0.00136	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HES1—epilepsy syndrome	0.000113	0.00135	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—COX3—epilepsy syndrome	0.000112	0.00134	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C19—epilepsy syndrome	0.000112	0.00134	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—epilepsy syndrome	0.000111	0.00133	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HBEGF—epilepsy syndrome	0.00011	0.00132	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HMOX1—epilepsy syndrome	0.000109	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—MEF2C—epilepsy syndrome	0.000109	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—CHRNA4—epilepsy syndrome	0.000108	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIK2—epilepsy syndrome	0.000108	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC1A3—epilepsy syndrome	0.000108	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—KCNJ11—epilepsy syndrome	0.000108	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLCO1A2—epilepsy syndrome	0.000106	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC8A2—epilepsy syndrome	0.000106	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC9A6—epilepsy syndrome	0.000106	0.00127	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—YWHAZ—epilepsy syndrome	0.000105	0.00126	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NGF—epilepsy syndrome	0.000104	0.00125	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GAD1—epilepsy syndrome	0.000104	0.00124	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—NR3C1—epilepsy syndrome	0.000104	0.00124	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—epilepsy syndrome	0.000102	0.00122	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GABRG2—epilepsy syndrome	0.000101	0.00121	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC8A3—epilepsy syndrome	0.000101	0.00121	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GABBR1—epilepsy syndrome	9.91e-05	0.00119	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HTR2A—epilepsy syndrome	9.9e-05	0.00119	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—AVP—epilepsy syndrome	9.72e-05	0.00116	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC6A1—epilepsy syndrome	9.66e-05	0.00116	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIN2A—epilepsy syndrome	9.66e-05	0.00116	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIA1—epilepsy syndrome	9.66e-05	0.00116	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—HMOX1—epilepsy syndrome	9.65e-05	0.00115	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—BCHE—epilepsy syndrome	9.56e-05	0.00114	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—SIRT1—epilepsy syndrome	9.53e-05	0.00114	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—APOD—epilepsy syndrome	9.34e-05	0.00112	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—DLG4—epilepsy syndrome	9.33e-05	0.00112	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNB2—epilepsy syndrome	9.15e-05	0.0011	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GRIN2B—epilepsy syndrome	9.12e-05	0.00109	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC1A1—epilepsy syndrome	9.1e-05	0.00109	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC12A2—epilepsy syndrome	9.1e-05	0.00109	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—PLCB1—epilepsy syndrome	9.02e-05	0.00108	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GABRA5—epilepsy syndrome	8.68e-05	0.00104	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—epilepsy syndrome	8.34e-05	0.000999	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ARHGEF9—epilepsy syndrome	8.32e-05	0.000996	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GABRB3—epilepsy syndrome	8.32e-05	0.000996	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC17A7—epilepsy syndrome	8.32e-05	0.000996	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GABRA1—epilepsy syndrome	8.32e-05	0.000996	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—CHRNA4—epilepsy syndrome	8.31e-05	0.000994	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—APOD—epilepsy syndrome	8.27e-05	0.00099	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC1A1—epilepsy syndrome	8.06e-05	0.000965	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC12A2—epilepsy syndrome	8.06e-05	0.000965	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC1A2—epilepsy syndrome	7.74e-05	0.000926	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GABRA5—epilepsy syndrome	7.69e-05	0.000921	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—epilepsy syndrome	7.39e-05	0.000885	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GABRB2—epilepsy syndrome	7.38e-05	0.000884	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GABRA1—epilepsy syndrome	7.37e-05	0.000883	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ARHGEF9—epilepsy syndrome	7.37e-05	0.000883	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC17A7—epilepsy syndrome	7.37e-05	0.000883	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GABRB3—epilepsy syndrome	7.37e-05	0.000883	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—BCHE—epilepsy syndrome	7.32e-05	0.000876	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AQP1—epilepsy syndrome	7.27e-05	0.000871	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—DLG4—epilepsy syndrome	7.15e-05	0.000855	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TRPV1—epilepsy syndrome	7.08e-05	0.000847	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NOS2—epilepsy syndrome	7e-05	0.000838	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GRIN2B—epilepsy syndrome	6.99e-05	0.000836	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—PLCB1—epilepsy syndrome	6.91e-05	0.000827	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC1A2—epilepsy syndrome	6.85e-05	0.00082	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC8A1—epilepsy syndrome	6.81e-05	0.000815	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—AVP—epilepsy syndrome	6.8e-05	0.000814	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AQP4—epilepsy syndrome	6.58e-05	0.000787	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC1A3—epilepsy syndrome	6.58e-05	0.000787	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GABRB2—epilepsy syndrome	6.54e-05	0.000783	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AQP1—epilepsy syndrome	6.44e-05	0.000771	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCC2—epilepsy syndrome	6.31e-05	0.000755	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TRPV1—epilepsy syndrome	6.27e-05	0.00075	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—epilepsy syndrome	6.06e-05	0.000726	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC8A1—epilepsy syndrome	6.03e-05	0.000722	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—AVP—epilepsy syndrome	6.02e-05	0.000721	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2C19—epilepsy syndrome	5.94e-05	0.000711	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP11A1—epilepsy syndrome	5.9e-05	0.000707	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—IL1B—epilepsy syndrome	5.87e-05	0.000703	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC6A1—epilepsy syndrome	5.86e-05	0.000702	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP2C19—epilepsy syndrome	5.86e-05	0.000701	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CASP3—epilepsy syndrome	5.86e-05	0.000701	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AQP4—epilepsy syndrome	5.83e-05	0.000698	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC1A3—epilepsy syndrome	5.83e-05	0.000698	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP11A1—epilepsy syndrome	5.82e-05	0.000697	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—JUN—epilepsy syndrome	5.69e-05	0.000681	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCC2—epilepsy syndrome	5.59e-05	0.000669	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—PRKCB—epilepsy syndrome	5.42e-05	0.000649	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	5.36e-05	0.000642	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	5.23e-05	0.000626	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC6A1—epilepsy syndrome	5.19e-05	0.000622	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—VEGFA—epilepsy syndrome	4.97e-05	0.000595	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—POMC—epilepsy syndrome	4.91e-05	0.000588	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	4.75e-05	0.000569	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—JUN—epilepsy syndrome	4.64e-05	0.000556	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	4.63e-05	0.000554	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	4.44e-05	0.000532	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TNF—epilepsy syndrome	4.26e-05	0.00051	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	4.24e-05	0.000507	CbGpPWpGaD
Methylphenidate—Dizziness—Zonisamide—epilepsy syndrome	4.17e-05	0.000121	CcSEcCtD
Methylphenidate—Headache—Diazepam—epilepsy syndrome	4.17e-05	0.000121	CcSEcCtD
Methylphenidate—Anxiety—Pregabalin—epilepsy syndrome	4.16e-05	0.000121	CcSEcCtD
Methylphenidate—Diarrhoea—Clonazepam—epilepsy syndrome	4.16e-05	0.000121	CcSEcCtD
Methylphenidate—Anaemia—Gabapentin—epilepsy syndrome	4.16e-05	0.00012	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—PRKCB—epilepsy syndrome	4.15e-05	0.000497	CbGpPWpGaD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	4.15e-05	0.00012	CcSEcCtD
Methylphenidate—Asthenia—Carbamazepine—epilepsy syndrome	4.14e-05	0.00012	CcSEcCtD
Methylphenidate—Agitation—Gabapentin—epilepsy syndrome	4.13e-05	0.00012	CcSEcCtD
Methylphenidate—Diarrhoea—Phenytoin—epilepsy syndrome	4.13e-05	0.00012	CcSEcCtD
Methylphenidate—Discomfort—Pregabalin—epilepsy syndrome	4.13e-05	0.00012	CcSEcCtD
Methylphenidate—Nausea—Fosphenytoin—epilepsy syndrome	4.12e-05	0.000119	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—ALB—epilepsy syndrome	4.12e-05	0.000493	CbGpPWpGaD
Methylphenidate—Diarrhoea—Oxcarbazepine—epilepsy syndrome	4.11e-05	0.000119	CcSEcCtD
Methylphenidate—Erythema multiforme—Topiramate—epilepsy syndrome	4.11e-05	0.000119	CcSEcCtD
Methylphenidate—Angioedema—Gabapentin—epilepsy syndrome	4.11e-05	0.000119	CcSEcCtD
Methylphenidate—Hypersensitivity—Lamotrigine—epilepsy syndrome	4.11e-05	0.000119	CcSEcCtD
Methylphenidate—Vomiting—Felbamate—epilepsy syndrome	4.1e-05	0.000119	CcSEcCtD
Methylphenidate—Dry mouth—Pregabalin—epilepsy syndrome	4.09e-05	0.000118	CcSEcCtD
Methylphenidate—Pruritus—Carbamazepine—epilepsy syndrome	4.08e-05	0.000118	CcSEcCtD
Methylphenidate—Rash—Felbamate—epilepsy syndrome	4.07e-05	0.000118	CcSEcCtD
Methylphenidate—Eye disorder—Topiramate—epilepsy syndrome	4.06e-05	0.000118	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—CA13—epilepsy syndrome	4.06e-05	0.000486	CbGpPWpGaD
Methylphenidate—Dermatitis—Felbamate—epilepsy syndrome	4.06e-05	0.000118	CcSEcCtD
Methylphenidate—Malaise—Gabapentin—epilepsy syndrome	4.06e-05	0.000117	CcSEcCtD
Methylphenidate—Vertigo—Gabapentin—epilepsy syndrome	4.04e-05	0.000117	CcSEcCtD
Methylphenidate—Headache—Felbamate—epilepsy syndrome	4.04e-05	0.000117	CcSEcCtD
Methylphenidate—Confusional state—Pregabalin—epilepsy syndrome	4.04e-05	0.000117	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	4.04e-05	0.000117	CcSEcCtD
Methylphenidate—Cardiac disorder—Topiramate—epilepsy syndrome	4.04e-05	0.000117	CcSEcCtD
Methylphenidate—Flushing—Topiramate—epilepsy syndrome	4.04e-05	0.000117	CcSEcCtD
Methylphenidate—Syncope—Gabapentin—epilepsy syndrome	4.03e-05	0.000117	CcSEcCtD
Methylphenidate—Leukopenia—Gabapentin—epilepsy syndrome	4.03e-05	0.000117	CcSEcCtD
Methylphenidate—Dizziness—Clonazepam—epilepsy syndrome	4.02e-05	0.000116	CcSEcCtD
Methylphenidate—Nausea—Vigabatrin—epilepsy syndrome	4.02e-05	0.000116	CcSEcCtD
Methylphenidate—Vomiting—Zonisamide—epilepsy syndrome	4.01e-05	0.000116	CcSEcCtD
Methylphenidate—Insomnia—Valproic Acid—epilepsy syndrome	4.01e-05	0.000116	CcSEcCtD
Methylphenidate—Anaphylactic shock—Pregabalin—epilepsy syndrome	4e-05	0.000116	CcSEcCtD
Methylphenidate—Oedema—Pregabalin—epilepsy syndrome	4e-05	0.000116	CcSEcCtD
Methylphenidate—Asthenia—Lamotrigine—epilepsy syndrome	4e-05	0.000116	CcSEcCtD
Methylphenidate—Dizziness—Phenytoin—epilepsy syndrome	4e-05	0.000116	CcSEcCtD
Methylphenidate—Rash—Zonisamide—epilepsy syndrome	3.98e-05	0.000115	CcSEcCtD
Methylphenidate—Infection—Pregabalin—epilepsy syndrome	3.98e-05	0.000115	CcSEcCtD
Methylphenidate—Paraesthesia—Valproic Acid—epilepsy syndrome	3.98e-05	0.000115	CcSEcCtD
Methylphenidate—Palpitations—Gabapentin—epilepsy syndrome	3.98e-05	0.000115	CcSEcCtD
Methylphenidate—Dermatitis—Zonisamide—epilepsy syndrome	3.98e-05	0.000115	CcSEcCtD
Methylphenidate—Dizziness—Oxcarbazepine—epilepsy syndrome	3.97e-05	0.000115	CcSEcCtD
Methylphenidate—Nausea—Diazepam—epilepsy syndrome	3.96e-05	0.000115	CcSEcCtD
Methylphenidate—Loss of consciousness—Gabapentin—epilepsy syndrome	3.95e-05	0.000115	CcSEcCtD
Methylphenidate—Headache—Zonisamide—epilepsy syndrome	3.95e-05	0.000115	CcSEcCtD
Methylphenidate—Dyspnoea—Valproic Acid—epilepsy syndrome	3.95e-05	0.000114	CcSEcCtD
Methylphenidate—Diarrhoea—Carbamazepine—epilepsy syndrome	3.95e-05	0.000114	CcSEcCtD
Methylphenidate—Angiopathy—Topiramate—epilepsy syndrome	3.95e-05	0.000114	CcSEcCtD
Methylphenidate—Pruritus—Lamotrigine—epilepsy syndrome	3.94e-05	0.000114	CcSEcCtD
Methylphenidate—Shock—Pregabalin—epilepsy syndrome	3.94e-05	0.000114	CcSEcCtD
Methylphenidate—Somnolence—Valproic Acid—epilepsy syndrome	3.94e-05	0.000114	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	3.94e-05	0.000471	CbGpPWpGaD
Methylphenidate—Immune system disorder—Topiramate—epilepsy syndrome	3.93e-05	0.000114	CcSEcCtD
Methylphenidate—Nervous system disorder—Pregabalin—epilepsy syndrome	3.93e-05	0.000114	CcSEcCtD
Methylphenidate—Cough—Gabapentin—epilepsy syndrome	3.93e-05	0.000114	CcSEcCtD
Methylphenidate—Thrombocytopenia—Pregabalin—epilepsy syndrome	3.92e-05	0.000114	CcSEcCtD
Methylphenidate—Mediastinal disorder—Topiramate—epilepsy syndrome	3.92e-05	0.000113	CcSEcCtD
Methylphenidate—Tachycardia—Pregabalin—epilepsy syndrome	3.91e-05	0.000113	CcSEcCtD
Methylphenidate—Chills—Topiramate—epilepsy syndrome	3.9e-05	0.000113	CcSEcCtD
Methylphenidate—Dyspepsia—Valproic Acid—epilepsy syndrome	3.9e-05	0.000113	CcSEcCtD
Methylphenidate—Convulsion—Gabapentin—epilepsy syndrome	3.9e-05	0.000113	CcSEcCtD
Methylphenidate—Skin disorder—Pregabalin—epilepsy syndrome	3.89e-05	0.000113	CcSEcCtD
Methylphenidate—Hypertension—Gabapentin—epilepsy syndrome	3.88e-05	0.000112	CcSEcCtD
Methylphenidate—Hyperhidrosis—Pregabalin—epilepsy syndrome	3.87e-05	0.000112	CcSEcCtD
Methylphenidate—Vomiting—Clonazepam—epilepsy syndrome	3.87e-05	0.000112	CcSEcCtD
Methylphenidate—Decreased appetite—Valproic Acid—epilepsy syndrome	3.85e-05	0.000112	CcSEcCtD
Methylphenidate—Alopecia—Topiramate—epilepsy syndrome	3.84e-05	0.000111	CcSEcCtD
Methylphenidate—Vomiting—Phenytoin—epilepsy syndrome	3.84e-05	0.000111	CcSEcCtD
Methylphenidate—Rash—Clonazepam—epilepsy syndrome	3.84e-05	0.000111	CcSEcCtD
Methylphenidate—Dermatitis—Clonazepam—epilepsy syndrome	3.83e-05	0.000111	CcSEcCtD
Methylphenidate—Arthralgia—Gabapentin—epilepsy syndrome	3.83e-05	0.000111	CcSEcCtD
Methylphenidate—Myalgia—Gabapentin—epilepsy syndrome	3.83e-05	0.000111	CcSEcCtD
Methylphenidate—Chest pain—Gabapentin—epilepsy syndrome	3.83e-05	0.000111	CcSEcCtD
Methylphenidate—Nausea—Felbamate—epilepsy syndrome	3.83e-05	0.000111	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.82e-05	0.000111	CcSEcCtD
Methylphenidate—Vomiting—Oxcarbazepine—epilepsy syndrome	3.82e-05	0.000111	CcSEcCtD
Methylphenidate—Fatigue—Valproic Acid—epilepsy syndrome	3.82e-05	0.000111	CcSEcCtD
Methylphenidate—Anxiety—Gabapentin—epilepsy syndrome	3.82e-05	0.000111	CcSEcCtD
Methylphenidate—Anorexia—Pregabalin—epilepsy syndrome	3.82e-05	0.000111	CcSEcCtD
Methylphenidate—Dizziness—Carbamazepine—epilepsy syndrome	3.81e-05	0.00011	CcSEcCtD
Methylphenidate—Diarrhoea—Lamotrigine—epilepsy syndrome	3.81e-05	0.00011	CcSEcCtD
Methylphenidate—Headache—Clonazepam—epilepsy syndrome	3.81e-05	0.00011	CcSEcCtD
Methylphenidate—Rash—Phenytoin—epilepsy syndrome	3.81e-05	0.00011	CcSEcCtD
Methylphenidate—Mental disorder—Topiramate—epilepsy syndrome	3.81e-05	0.00011	CcSEcCtD
Methylphenidate—Dermatitis—Phenytoin—epilepsy syndrome	3.81e-05	0.00011	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	3.8e-05	0.00011	CcSEcCtD
Methylphenidate—Rash—Oxcarbazepine—epilepsy syndrome	3.79e-05	0.00011	CcSEcCtD
Methylphenidate—Pain—Valproic Acid—epilepsy syndrome	3.79e-05	0.00011	CcSEcCtD
Methylphenidate—Constipation—Valproic Acid—epilepsy syndrome	3.79e-05	0.00011	CcSEcCtD
Methylphenidate—Dermatitis—Oxcarbazepine—epilepsy syndrome	3.79e-05	0.00011	CcSEcCtD
Methylphenidate—Headache—Phenytoin—epilepsy syndrome	3.79e-05	0.00011	CcSEcCtD
Methylphenidate—Erythema—Topiramate—epilepsy syndrome	3.79e-05	0.00011	CcSEcCtD
Methylphenidate—Malnutrition—Topiramate—epilepsy syndrome	3.79e-05	0.00011	CcSEcCtD
Methylphenidate—Discomfort—Gabapentin—epilepsy syndrome	3.78e-05	0.00011	CcSEcCtD
Methylphenidate—Headache—Oxcarbazepine—epilepsy syndrome	3.77e-05	0.000109	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	3.76e-05	0.00045	CbGpPWpGaD
Methylphenidate—Nausea—Zonisamide—epilepsy syndrome	3.75e-05	0.000109	CcSEcCtD
Methylphenidate—Dry mouth—Gabapentin—epilepsy syndrome	3.75e-05	0.000108	CcSEcCtD
Methylphenidate—Tension—Topiramate—epilepsy syndrome	3.71e-05	0.000108	CcSEcCtD
Methylphenidate—Confusional state—Gabapentin—epilepsy syndrome	3.7e-05	0.000107	CcSEcCtD
Methylphenidate—Dizziness—Lamotrigine—epilepsy syndrome	3.69e-05	0.000107	CcSEcCtD
Methylphenidate—Nervousness—Topiramate—epilepsy syndrome	3.68e-05	0.000106	CcSEcCtD
Methylphenidate—Anaphylactic shock—Gabapentin—epilepsy syndrome	3.67e-05	0.000106	CcSEcCtD
Methylphenidate—Oedema—Gabapentin—epilepsy syndrome	3.67e-05	0.000106	CcSEcCtD
Methylphenidate—Vomiting—Carbamazepine—epilepsy syndrome	3.67e-05	0.000106	CcSEcCtD
Methylphenidate—Back pain—Topiramate—epilepsy syndrome	3.66e-05	0.000106	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—ALB—epilepsy syndrome	3.65e-05	0.000437	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Valproic Acid—epilepsy syndrome	3.65e-05	0.000106	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	3.65e-05	0.000106	CcSEcCtD
Methylphenidate—Infection—Gabapentin—epilepsy syndrome	3.65e-05	0.000106	CcSEcCtD
Methylphenidate—Muscle spasms—Topiramate—epilepsy syndrome	3.64e-05	0.000105	CcSEcCtD
Methylphenidate—Rash—Carbamazepine—epilepsy syndrome	3.64e-05	0.000105	CcSEcCtD
Methylphenidate—Dermatitis—Carbamazepine—epilepsy syndrome	3.63e-05	0.000105	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	3.62e-05	0.000105	CcSEcCtD
Methylphenidate—Insomnia—Pregabalin—epilepsy syndrome	3.62e-05	0.000105	CcSEcCtD
Methylphenidate—Nausea—Clonazepam—epilepsy syndrome	3.61e-05	0.000105	CcSEcCtD
Methylphenidate—Headache—Carbamazepine—epilepsy syndrome	3.61e-05	0.000105	CcSEcCtD
Methylphenidate—Shock—Gabapentin—epilepsy syndrome	3.61e-05	0.000105	CcSEcCtD
Methylphenidate—Nervous system disorder—Gabapentin—epilepsy syndrome	3.6e-05	0.000104	CcSEcCtD
Methylphenidate—Paraesthesia—Pregabalin—epilepsy syndrome	3.6e-05	0.000104	CcSEcCtD
Methylphenidate—Thrombocytopenia—Gabapentin—epilepsy syndrome	3.6e-05	0.000104	CcSEcCtD
Methylphenidate—Nausea—Phenytoin—epilepsy syndrome	3.59e-05	0.000104	CcSEcCtD
Methylphenidate—Tachycardia—Gabapentin—epilepsy syndrome	3.58e-05	0.000104	CcSEcCtD
Methylphenidate—Dyspnoea—Pregabalin—epilepsy syndrome	3.57e-05	0.000103	CcSEcCtD
Methylphenidate—Nausea—Oxcarbazepine—epilepsy syndrome	3.57e-05	0.000103	CcSEcCtD
Methylphenidate—Vision blurred—Topiramate—epilepsy syndrome	3.57e-05	0.000103	CcSEcCtD
Methylphenidate—Skin disorder—Gabapentin—epilepsy syndrome	3.57e-05	0.000103	CcSEcCtD
Methylphenidate—Somnolence—Pregabalin—epilepsy syndrome	3.56e-05	0.000103	CcSEcCtD
Methylphenidate—Hyperhidrosis—Gabapentin—epilepsy syndrome	3.55e-05	0.000103	CcSEcCtD
Methylphenidate—Tremor—Topiramate—epilepsy syndrome	3.55e-05	0.000103	CcSEcCtD
Methylphenidate—Vomiting—Lamotrigine—epilepsy syndrome	3.54e-05	0.000103	CcSEcCtD
Methylphenidate—Urticaria—Valproic Acid—epilepsy syndrome	3.52e-05	0.000102	CcSEcCtD
Methylphenidate—Rash—Lamotrigine—epilepsy syndrome	3.51e-05	0.000102	CcSEcCtD
Methylphenidate—Ill-defined disorder—Topiramate—epilepsy syndrome	3.51e-05	0.000102	CcSEcCtD
Methylphenidate—Dermatitis—Lamotrigine—epilepsy syndrome	3.51e-05	0.000102	CcSEcCtD
Methylphenidate—Body temperature increased—Valproic Acid—epilepsy syndrome	3.5e-05	0.000101	CcSEcCtD
Methylphenidate—Abdominal pain—Valproic Acid—epilepsy syndrome	3.5e-05	0.000101	CcSEcCtD
Methylphenidate—Anorexia—Gabapentin—epilepsy syndrome	3.5e-05	0.000101	CcSEcCtD
Methylphenidate—Anaemia—Topiramate—epilepsy syndrome	3.5e-05	0.000101	CcSEcCtD
Methylphenidate—Headache—Lamotrigine—epilepsy syndrome	3.49e-05	0.000101	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	3.49e-05	0.000417	CbGpPWpGaD
Methylphenidate—Decreased appetite—Pregabalin—epilepsy syndrome	3.48e-05	0.000101	CcSEcCtD
Methylphenidate—Agitation—Topiramate—epilepsy syndrome	3.48e-05	0.000101	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.46e-05	0.0001	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AVP—epilepsy syndrome	3.46e-05	0.000414	CbGpPWpGaD
Methylphenidate—Fatigue—Pregabalin—epilepsy syndrome	3.45e-05	0.0001	CcSEcCtD
Methylphenidate—Nausea—Carbamazepine—epilepsy syndrome	3.43e-05	9.92e-05	CcSEcCtD
Methylphenidate—Constipation—Pregabalin—epilepsy syndrome	3.42e-05	9.92e-05	CcSEcCtD
Methylphenidate—Pain—Pregabalin—epilepsy syndrome	3.42e-05	9.92e-05	CcSEcCtD
Methylphenidate—Malaise—Topiramate—epilepsy syndrome	3.41e-05	9.89e-05	CcSEcCtD
Methylphenidate—Vertigo—Topiramate—epilepsy syndrome	3.4e-05	9.85e-05	CcSEcCtD
Methylphenidate—Syncope—Topiramate—epilepsy syndrome	3.39e-05	9.83e-05	CcSEcCtD
Methylphenidate—Leukopenia—Topiramate—epilepsy syndrome	3.39e-05	9.81e-05	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	3.35e-05	0.000401	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	3.35e-05	9.69e-05	CcSEcCtD
Methylphenidate—Palpitations—Topiramate—epilepsy syndrome	3.35e-05	9.69e-05	CcSEcCtD
Methylphenidate—Loss of consciousness—Topiramate—epilepsy syndrome	3.33e-05	9.63e-05	CcSEcCtD
Methylphenidate—Insomnia—Gabapentin—epilepsy syndrome	3.32e-05	9.62e-05	CcSEcCtD
Methylphenidate—Nausea—Lamotrigine—epilepsy syndrome	3.31e-05	9.59e-05	CcSEcCtD
Methylphenidate—Cough—Topiramate—epilepsy syndrome	3.3e-05	9.57e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Pregabalin—epilepsy syndrome	3.3e-05	9.56e-05	CcSEcCtD
Methylphenidate—Paraesthesia—Gabapentin—epilepsy syndrome	3.3e-05	9.55e-05	CcSEcCtD
Methylphenidate—Convulsion—Topiramate—epilepsy syndrome	3.28e-05	9.5e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Pregabalin—epilepsy syndrome	3.27e-05	9.48e-05	CcSEcCtD
Methylphenidate—Dyspnoea—Gabapentin—epilepsy syndrome	3.27e-05	9.48e-05	CcSEcCtD
Methylphenidate—Hypertension—Topiramate—epilepsy syndrome	3.27e-05	9.46e-05	CcSEcCtD
Methylphenidate—Somnolence—Gabapentin—epilepsy syndrome	3.26e-05	9.45e-05	CcSEcCtD
Methylphenidate—Hypersensitivity—Valproic Acid—epilepsy syndrome	3.26e-05	9.45e-05	CcSEcCtD
Methylphenidate—Dyspepsia—Gabapentin—epilepsy syndrome	3.23e-05	9.36e-05	CcSEcCtD
Methylphenidate—Myalgia—Topiramate—epilepsy syndrome	3.22e-05	9.33e-05	CcSEcCtD
Methylphenidate—Arthralgia—Topiramate—epilepsy syndrome	3.22e-05	9.33e-05	CcSEcCtD
Methylphenidate—Chest pain—Topiramate—epilepsy syndrome	3.22e-05	9.33e-05	CcSEcCtD
Methylphenidate—Anxiety—Topiramate—epilepsy syndrome	3.21e-05	9.3e-05	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	3.2e-05	9.27e-05	CcSEcCtD
Methylphenidate—Decreased appetite—Gabapentin—epilepsy syndrome	3.19e-05	9.24e-05	CcSEcCtD
Methylphenidate—Discomfort—Topiramate—epilepsy syndrome	3.18e-05	9.22e-05	CcSEcCtD
Methylphenidate—Urticaria—Pregabalin—epilepsy syndrome	3.18e-05	9.21e-05	CcSEcCtD
Methylphenidate—Asthenia—Valproic Acid—epilepsy syndrome	3.18e-05	9.2e-05	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	3.17e-05	9.18e-05	CcSEcCtD
Methylphenidate—Fatigue—Gabapentin—epilepsy syndrome	3.17e-05	9.17e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Pregabalin—epilepsy syndrome	3.17e-05	9.17e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Pregabalin—epilepsy syndrome	3.17e-05	9.17e-05	CcSEcCtD
Methylphenidate—Dry mouth—Topiramate—epilepsy syndrome	3.15e-05	9.13e-05	CcSEcCtD
Methylphenidate—Pain—Gabapentin—epilepsy syndrome	3.14e-05	9.09e-05	CcSEcCtD
Methylphenidate—Constipation—Gabapentin—epilepsy syndrome	3.14e-05	9.09e-05	CcSEcCtD
Methylphenidate—Pruritus—Valproic Acid—epilepsy syndrome	3.13e-05	9.08e-05	CcSEcCtD
Methylphenidate—Confusional state—Topiramate—epilepsy syndrome	3.12e-05	9.02e-05	CcSEcCtD
Methylphenidate—Oedema—Topiramate—epilepsy syndrome	3.09e-05	8.95e-05	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	3.09e-05	0.00037	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CERS1—epilepsy syndrome	3.08e-05	0.000369	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PDXK—epilepsy syndrome	3.08e-05	0.000369	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GLUD1—epilepsy syndrome	3.08e-05	0.000369	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—L2HGDH—epilepsy syndrome	3.08e-05	0.000369	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADK—epilepsy syndrome	3.08e-05	0.000369	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—FAR1—epilepsy syndrome	3.08e-05	0.000369	CbGpPWpGaD
Methylphenidate—Infection—Topiramate—epilepsy syndrome	3.07e-05	8.89e-05	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AVP—epilepsy syndrome	3.06e-05	0.000366	CbGpPWpGaD
Methylphenidate—Shock—Topiramate—epilepsy syndrome	3.04e-05	8.8e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Valproic Acid—epilepsy syndrome	3.03e-05	8.78e-05	CcSEcCtD
Methylphenidate—Nervous system disorder—Topiramate—epilepsy syndrome	3.03e-05	8.77e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Gabapentin—epilepsy syndrome	3.03e-05	8.76e-05	CcSEcCtD
Methylphenidate—Thrombocytopenia—Topiramate—epilepsy syndrome	3.02e-05	8.76e-05	CcSEcCtD
Methylphenidate—Tachycardia—Topiramate—epilepsy syndrome	3.02e-05	8.73e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Gabapentin—epilepsy syndrome	3e-05	8.7e-05	CcSEcCtD
Methylphenidate—Skin disorder—Topiramate—epilepsy syndrome	3e-05	8.69e-05	CcSEcCtD
Methylphenidate—Hyperhidrosis—Topiramate—epilepsy syndrome	2.99e-05	8.65e-05	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	2.97e-05	0.000355	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Pregabalin—epilepsy syndrome	2.95e-05	8.54e-05	CcSEcCtD
Methylphenidate—Anorexia—Topiramate—epilepsy syndrome	2.94e-05	8.53e-05	CcSEcCtD
Methylphenidate—Dizziness—Valproic Acid—epilepsy syndrome	2.93e-05	8.48e-05	CcSEcCtD
Methylphenidate—Urticaria—Gabapentin—epilepsy syndrome	2.92e-05	8.45e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Gabapentin—epilepsy syndrome	2.9e-05	8.41e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Gabapentin—epilepsy syndrome	2.9e-05	8.41e-05	CcSEcCtD
Methylphenidate—Asthenia—Pregabalin—epilepsy syndrome	2.87e-05	8.32e-05	CcSEcCtD
Methylphenidate—Pruritus—Pregabalin—epilepsy syndrome	2.83e-05	8.2e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—NHLRC1—epilepsy syndrome	2.82e-05	0.000337	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PNPO—epilepsy syndrome	2.82e-05	0.000337	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GAMT—epilepsy syndrome	2.82e-05	0.000337	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—EPM2A—epilepsy syndrome	2.82e-05	0.000337	CbGpPWpGaD
Methylphenidate—Vomiting—Valproic Acid—epilepsy syndrome	2.82e-05	8.16e-05	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	2.81e-05	8.15e-05	CcSEcCtD
Methylphenidate—Insomnia—Topiramate—epilepsy syndrome	2.79e-05	8.09e-05	CcSEcCtD
Methylphenidate—Rash—Valproic Acid—epilepsy syndrome	2.79e-05	8.09e-05	CcSEcCtD
Methylphenidate—Dermatitis—Valproic Acid—epilepsy syndrome	2.79e-05	8.08e-05	CcSEcCtD
Methylphenidate—Headache—Valproic Acid—epilepsy syndrome	2.77e-05	8.04e-05	CcSEcCtD
Methylphenidate—Paraesthesia—Topiramate—epilepsy syndrome	2.77e-05	8.03e-05	CcSEcCtD
Methylphenidate—Dyspnoea—Topiramate—epilepsy syndrome	2.75e-05	7.98e-05	CcSEcCtD
Methylphenidate—Somnolence—Topiramate—epilepsy syndrome	2.75e-05	7.95e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Pregabalin—epilepsy syndrome	2.74e-05	7.93e-05	CcSEcCtD
Methylphenidate—Dyspepsia—Topiramate—epilepsy syndrome	2.72e-05	7.88e-05	CcSEcCtD
Methylphenidate—Hypersensitivity—Gabapentin—epilepsy syndrome	2.71e-05	7.83e-05	CcSEcCtD
Methylphenidate—Decreased appetite—Topiramate—epilepsy syndrome	2.69e-05	7.78e-05	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.67e-05	7.72e-05	CcSEcCtD
Methylphenidate—Fatigue—Topiramate—epilepsy syndrome	2.66e-05	7.71e-05	CcSEcCtD
Methylphenidate—Dizziness—Pregabalin—epilepsy syndrome	2.65e-05	7.67e-05	CcSEcCtD
Methylphenidate—Pain—Topiramate—epilepsy syndrome	2.64e-05	7.65e-05	CcSEcCtD
Methylphenidate—Constipation—Topiramate—epilepsy syndrome	2.64e-05	7.65e-05	CcSEcCtD
Methylphenidate—Asthenia—Gabapentin—epilepsy syndrome	2.63e-05	7.63e-05	CcSEcCtD
Methylphenidate—Nausea—Valproic Acid—epilepsy syndrome	2.63e-05	7.62e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—QDPR—epilepsy syndrome	2.62e-05	0.000313	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CA4—epilepsy syndrome	2.62e-05	0.000313	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—POMC—epilepsy syndrome	2.61e-05	0.000312	CbGpPWpGaD
Methylphenidate—Pruritus—Gabapentin—epilepsy syndrome	2.6e-05	7.52e-05	CcSEcCtD
Methylphenidate—Vomiting—Pregabalin—epilepsy syndrome	2.55e-05	7.37e-05	CcSEcCtD
Methylphenidate—Feeling abnormal—Topiramate—epilepsy syndrome	2.55e-05	7.37e-05	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.53e-05	7.32e-05	CcSEcCtD
Methylphenidate—Rash—Pregabalin—epilepsy syndrome	2.52e-05	7.31e-05	CcSEcCtD
Methylphenidate—Dermatitis—Pregabalin—epilepsy syndrome	2.52e-05	7.31e-05	CcSEcCtD
Methylphenidate—Diarrhoea—Gabapentin—epilepsy syndrome	2.51e-05	7.28e-05	CcSEcCtD
Methylphenidate—Headache—Pregabalin—epilepsy syndrome	2.51e-05	7.26e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—COX3—epilepsy syndrome	2.46e-05	0.000295	CbGpPWpGaD
Methylphenidate—Urticaria—Topiramate—epilepsy syndrome	2.45e-05	7.11e-05	CcSEcCtD
Methylphenidate—Abdominal pain—Topiramate—epilepsy syndrome	2.44e-05	7.07e-05	CcSEcCtD
Methylphenidate—Body temperature increased—Topiramate—epilepsy syndrome	2.44e-05	7.07e-05	CcSEcCtD
Methylphenidate—Dizziness—Gabapentin—epilepsy syndrome	2.43e-05	7.03e-05	CcSEcCtD
Methylphenidate—Nausea—Pregabalin—epilepsy syndrome	2.38e-05	6.89e-05	CcSEcCtD
Methylphenidate—Vomiting—Gabapentin—epilepsy syndrome	2.33e-05	6.76e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—SLC6A8—epilepsy syndrome	2.33e-05	0.000279	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—KCNB1—epilepsy syndrome	2.33e-05	0.000279	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PFKL—epilepsy syndrome	2.33e-05	0.000279	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLCO1A2—epilepsy syndrome	2.33e-05	0.000279	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CACNA2D2—epilepsy syndrome	2.33e-05	0.000279	CbGpPWpGaD
Methylphenidate—Rash—Gabapentin—epilepsy syndrome	2.32e-05	6.7e-05	CcSEcCtD
Methylphenidate—Dermatitis—Gabapentin—epilepsy syndrome	2.31e-05	6.7e-05	CcSEcCtD
Methylphenidate—Headache—Gabapentin—epilepsy syndrome	2.3e-05	6.66e-05	CcSEcCtD
Methylphenidate—Hypersensitivity—Topiramate—epilepsy syndrome	2.28e-05	6.59e-05	CcSEcCtD
Methylphenidate—Asthenia—Topiramate—epilepsy syndrome	2.22e-05	6.42e-05	CcSEcCtD
Methylphenidate—Pruritus—Topiramate—epilepsy syndrome	2.19e-05	6.33e-05	CcSEcCtD
Methylphenidate—Nausea—Gabapentin—epilepsy syndrome	2.18e-05	6.32e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—UPB1—epilepsy syndrome	2.13e-05	0.000255	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ATIC—epilepsy syndrome	2.13e-05	0.000255	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NEU1—epilepsy syndrome	2.13e-05	0.000255	CbGpPWpGaD
Methylphenidate—Diarrhoea—Topiramate—epilepsy syndrome	2.11e-05	6.12e-05	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ALB—epilepsy syndrome	2.09e-05	0.000251	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HSD17B4—epilepsy syndrome	2.05e-05	0.000246	CbGpPWpGaD
Methylphenidate—Dizziness—Topiramate—epilepsy syndrome	2.04e-05	5.92e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—GBE1—epilepsy syndrome	1.98e-05	0.000238	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPP1R3C—epilepsy syndrome	1.98e-05	0.000238	CbGpPWpGaD
Methylphenidate—Vomiting—Topiramate—epilepsy syndrome	1.96e-05	5.69e-05	CcSEcCtD
Methylphenidate—Rash—Topiramate—epilepsy syndrome	1.95e-05	5.64e-05	CcSEcCtD
Methylphenidate—Dermatitis—Topiramate—epilepsy syndrome	1.95e-05	5.64e-05	CcSEcCtD
Methylphenidate—Headache—Topiramate—epilepsy syndrome	1.94e-05	5.6e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—ASAH1—epilepsy syndrome	1.87e-05	0.000223	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.85e-05	0.000222	CbGpPWpGaD
Methylphenidate—Nausea—Topiramate—epilepsy syndrome	1.84e-05	5.31e-05	CcSEcCtD
Methylphenidate—CYP2D6—Metabolism—STXBP1—epilepsy syndrome	1.81e-05	0.000217	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALAD—epilepsy syndrome	1.77e-05	0.000212	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NT5E—epilepsy syndrome	1.77e-05	0.000212	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALDH7A1—epilepsy syndrome	1.69e-05	0.000202	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CACNA1A—epilepsy syndrome	1.69e-05	0.000202	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ST3GAL3—epilepsy syndrome	1.65e-05	0.000198	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADSL—epilepsy syndrome	1.62e-05	0.000194	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GLUL—epilepsy syndrome	1.59e-05	0.00019	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CACNA1D—epilepsy syndrome	1.56e-05	0.000186	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TXNRD1—epilepsy syndrome	1.46e-05	0.000174	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AQP1—epilepsy syndrome	1.41e-05	0.000169	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	1.28e-05	0.000153	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	1.28e-05	0.000153	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	1.04e-05	0.000125	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.02e-05	0.000122	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.01e-05	0.000121	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	8.67e-06	0.000104	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—BCHE—epilepsy syndrome	8.64e-06	0.000103	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	8.24e-06	9.86e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	8.15e-06	9.76e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TH—epilepsy syndrome	8.12e-06	9.72e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	6.78e-06	8.11e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CAT—epilepsy syndrome	6.69e-06	8e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	6.51e-06	7.79e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GPX1—epilepsy syndrome	6.05e-06	7.24e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AGT—epilepsy syndrome	5.3e-06	6.35e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—APOE—epilepsy syndrome	5.2e-06	6.22e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—POMC—epilepsy syndrome	4.46e-06	5.34e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALB—epilepsy syndrome	4.07e-06	4.87e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	3.56e-06	4.26e-05	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—AKT1—epilepsy syndrome	1.79e-06	2.14e-05	CbGpPWpGaD
